<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-ICA-2467</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-2467</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Динамика иммунных изменений в очаге повреждения при оксазолон-индуцированном язвенном колите на фоне озонотерапии</article-title><trans-title-group xml:lang="en"><trans-title>Immune changes at the injured sites in oxazolone-induced ulcerous colitis: Influence of ozone therapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Давыдова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Davydova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Давыдова Евгения Валерьевна – доктор медицинских наук, доцент, профессор кафедры патологической физиологии</p><p>454048, г. Челябинск, ул. Воровского, 64</p></bio><bio xml:lang="en"><p>Davydova Evgeniya V., PhD, MD (Medicine), Associate Professor, Professor, Department of Pathological Physiology</p><p>454048, Chelyabinsk, Vorovsky str., 64</p></bio><email xlink:type="simple">davidova-ev.med@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Осиков</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Osikov</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Осиков Михаил Владимирович – доктор медицинских наук, профессор, заведующий кафедрой патологической физиологии</p><p>Челябинск</p></bio><bio xml:lang="en"><p>PhD, MD (Medicine), Professor, Head, Department of Pathological Physiology</p><p>Chelyabinsk</p></bio><email xlink:type="simple">prof.osikov@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кайгородцева</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kaigorodtseva</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кайгородцева Наталья Васильевна – ассистент кафедры патологической физиологии</p><p>Челябинск</p></bio><bio xml:lang="en"><p>Assistant Professor, Department of Pathological Physiology</p><p>Chelyabinsk</p></bio><email xlink:type="simple">nkaigorodceva@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Южно-Уральский государственный медицинский университет» Министерства здравоохранения РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>South Ural State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>20</day><month>04</month><year>2022</year></pub-date><volume>24</volume><issue>2</issue><fpage>379</fpage><lpage>388</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Давыдова Е.В., Осиков М.В., Кайгородцева Н.В., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Давыдова Е.В., Осиков М.В., Кайгородцева Н.В.</copyright-holder><copyright-holder xml:lang="en">Davydova E.V., Osikov M.V., Kaigorodtseva N.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/2467">https://www.mimmun.ru/mimmun/article/view/2467</self-uri><abstract><p>Ключевыми звеньями патогенеза воспалительных заболеваний кишечника являются нарушение иммунорегуляции и формирование аутоиммунного профиля ответа по отношению к антигенам собственной кишечной микробиоты и воспалительно-измененным антигенам колоноцитов. Мультимодальные биологические эффекты озона являются основанием для применения локальной и системной озонотерапии в комплексном лечении практически любых воспалительных заболеваний желудочно-кишечного тракта. Цель работы – изучить влияние внутрибрюшинной и ректальной озонотерапии на иммунные показатели очага повреждения при оксазолон-индуцированном язвенном колите в динамике эксперимента. Исследование проводили на 64 половозрелых крысах-самцах чистой линии Wistar массой 240±20 г. Моделирование язвенного колита проводилось с помощью оксазолона (4-этоксиметилен-2-фенил2-оксазолин-5-он) (Sigma-Аldrich, США). Озоно-кислородную смесь вводили внутрибрюшинно или ректально в концентрации 1,0-1,2 мг/л ежедневно, 1 раз в сутки, в объеме 10 мл, курс 6 дней. Исходы эксперимента фиксировали на 2-е, 4-е и 6-е сутки. Концентрацию IL-17 и IL-23 определяли в гомогенате тканей кишечника (Bender Medsystems, Австрия) на анализаторе Personal LAB, экспрессию CD4 и FoxP3 на лимфоцитах кишечника иммуногистохимически (ElisaKit, Сhina) Повреждение тканей толстого кишечника в динамике оксазолон-индуцированного язвенного колита нарастало от 2-х к 6-м суткам. Общее количество лимфоцитов значимо увеличивалось в динамике экспериментального колита с параллельным снижением численности CD4+ лимфоцитов и FoxP3- позитивных Т-лимфоцитов. Концентрация IL-17 и IL-23 в тканях нарастала по мере выраженности воспалительных изменений в очаге повреждения. Внутрибрюшинное введение озона значимо снизило уровень лимфоцитов в тканях очага поражения на 6-е сутки, с нормализацией количества CD4+ и FoxP3-позитивных Т-лимфоцитов к 6-м суткам. Уровни IL-17 и IL-23 нарастали от 2-х к 6-м суткам, с более низким значением IL-23 на 6-е сутки в сравнении с группой животных без лечения. Ректальное введение ОКС привело к нормализации FoxP3-клеток на на 6-е сутки относительно интактных. Уровни провоспалительных цитокинов IL-17 и IL-23 значимо снижались на 6-е сутки в сравнении с группой животных без лечения, что, вероятно, связано с проявлением противовоспалительных свойств у озона.</p><p> </p></abstract><trans-abstract xml:lang="en"><p>Impaired immunoregulation and development of autoimmune response to antigens of own intestinal microbiota and inflammation-altered antigens of colonic cells represent the key links in pathogenesis of inflammatory bowel diseases. Multimodal biological effects of ozone presunme the usage of local and systemic ozone therapy in complex treatment of many inflammatory diseases of the gastrointestinal tract. The aim of our work was to study effects of intraperitoneal and rectal ozone therapy upon immune parameters of the lesion focus in oxazolone-induced ulcerative colitis in the course of time. The study was carried out on 64 adult male inbred Wistar rats weighing 240±20 g. Experimental ulcerative colitis was produced by oxazolone treatment (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one) (SigmaAldrich, USA). The ozone-oxygen mixture was injected intraperitoneally or rectally at a concentration of 1.0-1.2 mg/l, once a day, in a volume of 10 ml, at the 6-day course. The results of experiments were recorded on the days +2, +4 and +6. The concentrations of IL-17 and IL-23 was determined in a homogenate of intestinal tissues (Bender Medsystems, Austria) using a Personal LAB analyzer; expression of CD4 and FoxP3 on intestinal lymphocytes was determined by immunohistochemistry technique (ElisaKit, China). The observed tissue damage of large intestine showed an increase from day 2 to day 6 of oxazolone-induced ulcerative colitis. The total number of lymphocytes significantly increased upon development of experimental colitis, with parallel decrease in the number of CD4+ lymphocytes and FoxP3-positive T lymphocytes. IL-17 and IL-23 concentrations in the tissues increased with the severity of inflammatory changes in the lesion focus. Intraperitoneal ozone administration was associated with significant reduction of lymphocyte contents in the damaged tissues on the 6th day, whereas the numbers of CD4+ and FoxP3 positive T lymphocytes normalized by the 6th day. The levels of IL-17 and IL-23 increased from day 2 to day 6, with a lower IL-23 values on day 6 as compared with non-treated animals. Rectal administration of ACS led to the normalization of FoxP3 cells on the 6th day to the values of intact animals. The levels of proinflammatory cytokines (IL-17 and IL-23) significantly decreased on the 6th day as compared to the group of animals without treatment, which could be due to anti-inflammatory properties of ozone.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>оксазолон</kwd><kwd>колит</kwd><kwd>гомогенат</kwd><kwd>IL-17</kwd><kwd>IL-23</kwd><kwd>Т-хелперы</kwd><kwd>Т-регуляторные лимфоциты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>oxazolone</kwd><kwd>colitis</kwd><kwd>homogenate</kwd><kwd>IL-17</kwd><kwd>IL-23</kwd><kwd>T helpers</kwd><kwd>T regulatory lymphocytes</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Жеребятьев А.С., Камышный А.М. Транскрипционные регуляторы дифференцировки Т-лимфоцитов и паттернраспознающие рецепторы – экспрессия лимфоцитами кишечника при оксазолоновом колите у крыс и после введения ингибитора 3-гидрокси-3-метилглутарил коэнзим А-редуктазы и антагониста рецепторов интерлейкина-1 // Иммунология, 2015. Т. 36, № 3. С. 139-144.</mixed-citation><mixed-citation xml:lang="en">Zherebyatiev A.S., Kamyshnyi A.M. Transcriptional regulators of T-lymphocyte differentiation and pattern recognition receptors – expression by intestinal lymphocytes in oxazolone colitis in rats and after administration of an inhibitor of 3-hydroxy-3- methylglutaryl coenzyme A-reductase and an antagonist of interleukin-1 receptors. Immunologiya = Immunologiya, 2015, Vol. 36, no. 3, pp. 139-144. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Лазебник Л.Б., Парфенов А.И., Князев О.В., Коноплянников А.Г., Сагынбаева В.Э., Яковлева М.В., Астрелина Т.А., Ручкина И.Н., Щербаков П.Л., Трубицына И.Е., Царегородцева Т.М., Гудкова Р.Б., Рогозина В.А., Чикунова Б.З., Хомерики С.Г., Михайлова З.Ф. Биологическая терапия воспалительных заболеваний кишечника // ЭиКГ, 2011. № 3. С. 42-53.</mixed-citation><mixed-citation xml:lang="en">Lazebnik L.B., Parfenov A.I., Knyazev O.V., Konoplyannikov A.G., Sagynbaeva V.E., Yakovleva M.V., Astrelin T.A., Ruchkina I.N., Shcherbakov P.L., Trubitsyna I.E., Tsaregorodtseva T.M., Gudkova R.B., Rogozina V.A., Chikunova B.Z., Khomeriki S.G., Mikhailova Z.F. Biological therapy of inflammatory intestinal diseases. EiKG = Experimental and Clinical Gastroenterology, 2011, no. 3, pp. 42-53. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Осиков М.В., Симонян Е.В., Листик Е.В., Бакеева А.Е., Бивалькевич В.А. Воспалительные заболевания кишечника: выбор оптимальной экспериментальной модели // Современные проблемы науки и образования, 2017. № 3. [Электронный ресурс]. Режим доступа: https://science-education.ru/ru/article/view?id=26524.</mixed-citation><mixed-citation xml:lang="en">Osikov M.V., Simonyan E.V., Listik E.V., Bakeeva A.E., Bivalkevich V.A. Inflammatory bowel diseases: the choice of the optimal experimental model. Sovremennye problemy nauki i obrazovaniya = Modern Problems of Science and Education, 2017, no. 3. [Electronic resource]. Access mode: https://science-education.ru/ru/article/view?id=26524. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ситкин С.И., Вахитов Т.Я., Демьянова Е.В. Микробиом, дисбиоз толстой кишки и воспалительные заболевания кишечника: когда функция важнее таксономии // Альманах клинической медицины, 2018. T. 46, № 5. С. 396-425.</mixed-citation><mixed-citation xml:lang="en">Sitkin S.I., Vakhitov T.Ya., Demyanova E.V. Microbiome, colon dysbiosis and inflammatory bowel disease: when function is more important than taxonomy. Almanakh klinicheskoy meditsiny = Almanac of Clinical Medicine, 2018, Vol. 46, no. 5, pp. 396-425. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ткачев А.В., Мкртчян Л.С., Беловолова Р.А., Девликамова Т.А. Диагностическая значимость иммунологических маркеров при различных формах язвенного колита // Медицинский вестник Северного Кавказа, 2019. Т. 14, № 2. С. 334-338.</mixed-citation><mixed-citation xml:lang="en">Tkachev A.V., Mkrtchyan L.S., Belovolova R.A., Devlikamova T.A. Diagnostic value of immunological markers in various forms of ulcerative colitis. Meditsinskiy vestnik Severnogo Kavkaza = Medical News of North Caucasus, 2019, Vol. 14, no. 2, pp. 334-338. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Третьякова Ю.И. Особенности иммуновоспалительного синдрома у пациентов с язвенным колитом в зависимости от тяжести атаки заболевания // Пермский медицинский журнал, 2018. Т. 35, № 4. С. 39-45.</mixed-citation><mixed-citation xml:lang="en">Tretyakova Yu.I. Features of the immune-inflammatory syndrome in patients with ulcerative colitis, depending on the severity of the disease attack. Permskiy meditsinskiy zhurnal = Perm Medical Journal, 2018, Vol. 35, no. 4, pp. 39-45. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bai Z., Li X., Liu Y. , Deng J., Wang Ch., Li Y., Qi X. Successful treatment of acute-on-chronic liver failure and hemolytic anemia with hepato-protective drugs in combination with intravenous ozone without steroids: A case report. Intractable Rare Dis. Res., 2018, Vol. 7, no. 3, pp. 204-208.</mixed-citation><mixed-citation xml:lang="en">Bai Z., Li X., Liu Y. , Deng J., Wang Ch., Li Y., Qi X. Successful treatment of acute-on-chronic liver failure and hemolytic anemia with hepato-protective drugs in combination with intravenous ozone without steroids: A case report. Intractable Rare Dis. Res., 2018, Vol. 7, no. 3, pp. 204-208.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Bocci V., Valacchi G. Nrf2 activation as target to implement therapeutic treatments. Front. Chem., 2015, Vol. 3, 4. doi: 10.3389/fchem.2015.00004.</mixed-citation><mixed-citation xml:lang="en">Bocci V., Valacchi G. Nrf2 activation as target to implement therapeutic treatments. Front. Chem., 2015, Vol. 3, 4. doi: 10.3389/fchem.2015.00004.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Clavo B.N., Santana-Rodríguez P., Llontop P., Gutiérrez D., Suárez G., López L., Rovira G., MartínezSánchez G., González E., Jorge I.J., Perera C., Blanco J., Rodríguez-Esparragón F. Ozone therapy as adjuvant for cancer treatment: is further research warranted? Evid. Based Complement. Alternat. Med., 2018, Vol. 2018, 7931849. doi: 10.1155/2018/7931849.</mixed-citation><mixed-citation xml:lang="en">Clavo B.N., Santana-Rodríguez P., Llontop P., Gutiérrez D., Suárez G., López L., Rovira G., MartínezSánchez G., González E., Jorge I.J., Perera C., Blanco J., Rodríguez-Esparragón F. Ozone therapy as adjuvant for cancer treatment: is further research warranted? Evid. Based Complement. Alternat. Med., 2018, Vol. 2018, 7931849. doi: 10.1155/2018/7931849.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kim Y.M., Pae H.O., Park J.E., Lee Y.C., Woo J.M., Kim N.-H., Choi Y.K., Lee B.-S., Kim S.R., Chung H.-T. Heme oxygenase in the regulation of vascular biology: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal, 2011, Vol. 14, no. 1, pp. 137-167.</mixed-citation><mixed-citation xml:lang="en">Kim Y.M., Pae H.O., Park J.E., Lee Y.C., Woo J.M., Kim N.-H., Choi Y.K., Lee B.-S., Kim S.R., Chung H.-T. Heme oxygenase in the regulation of vascular biology: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal, 2011, Vol. 14, no. 1, pp. 137-167.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Lamas B., Richard M.L., Leducq V., Pham H.P., Michel M.L., Da Costa G., Bridonneau C., Jegou S., Hoffmann T.W., Natividad J.M., Brot L., Taleb S., Couturier-Maillard A., Nion-Larmurier I., Merabtene F., Seksik P., Bourrier A., Cosnes J., Ryffel B., Beaugerie L., Launay J.M., Langella P., Xavier R.J., Sokol H. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat. Med., 2016, Vol. 22, no. 6, pp. 598-605.</mixed-citation><mixed-citation xml:lang="en">Lamas B., Richard M.L., Leducq V., Pham H.P., Michel M.L., Da Costa G., Bridonneau C., Jegou S., Hoffmann T.W., Natividad J.M., Brot L., Taleb S., Couturier-Maillard A., Nion-Larmurier I., Merabtene F., Seksik P., Bourrier A., Cosnes J., Ryffel B., Beaugerie L., Launay J.M., Langella P., Xavier R.J., Sokol H. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat. Med., 2016, Vol. 22, no. 6, pp. 598-605.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Lee Y.K., Mazmanian S.K. Has the microbiota played a critical role in the evolution of the adaptive immune system? Science, 2010, Vol. 330, no. 6012, pp. 1768-7173.</mixed-citation><mixed-citation xml:lang="en">Lee Y.K., Mazmanian S.K. Has the microbiota played a critical role in the evolution of the adaptive immune system? Science, 2010, Vol. 330, no. 6012, pp. 1768-7173.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Manoto S.L., Maepa M.J., Motaung S.K. Medical ozone therapy as a potential treatment modality for regeneration of damaged articular cartilage in osteoarthritis. Saudi J. Biol. Sci., 2018, Vol. 25, no. 4, pp. 672-679.</mixed-citation><mixed-citation xml:lang="en">Manoto S.L., Maepa M.J., Motaung S.K. Medical ozone therapy as a potential treatment modality for regeneration of damaged articular cartilage in osteoarthritis. Saudi J. Biol. Sci., 2018, Vol. 25, no. 4, pp. 672-679.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Orakdogen M., Uslu S., Emon S.T., Somay H., Meric Z.C., Hakan T. The effect of ozone therapy on experimental vasospasm in the rat femoral artery. Turk. Neurosurg., 2016, Vol. 26, no. 6, pp. 860-865.</mixed-citation><mixed-citation xml:lang="en">Orakdogen M., Uslu S., Emon S.T., Somay H., Meric Z.C., Hakan T. The effect of ozone therapy on experimental vasospasm in the rat femoral artery. Turk. Neurosurg., 2016, Vol. 26, no. 6, pp. 860-865.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Wirtz S., Neufert C., Weigmann B., Neurath M.F. Chemically induced mouse models of intestinal inflammation. Nat. Protoc., 2007, Vol. 2, no. 3, pp. 541-600.</mixed-citation><mixed-citation xml:lang="en">Wirtz S., Neufert C., Weigmann B., Neurath M.F. Chemically induced mouse models of intestinal inflammation. Nat. Protoc., 2007, Vol. 2, no. 3, pp. 541-600.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
